Evidence map›Paper›PMID 31196173›Full record

ArticleStem cell research & therapy2019

Examining the fundamental biology of a novel population of directly reprogrammed human neural precursor cells.

Jan-Eric Ahlfors, Ashkan Azimi, Rouwayda El-Ayoubi, Alexander Velumian, Ilan Vonderwalde, Cecile Boscher, Oana Mihai, Sarathi Mani, Marina Samoilova, Mohamad Khazaei and 2 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Bridging the gap: a translational perspective in spinal cord injury.Experimental biology and medicine (Maywood, N.J.) · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Cellular reprogramming: Mathematics meets medicine.Wiley interdisciplinary reviews. Systems biology and medicine · 2020
    Review
  11. Article
  12. Direct cell-fate conversion of somatic cells: Toward regenerative medicine and industries.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jan-Eric AhlforsNew World Laboratories, Laval, Quebec, H7V 5B7, Canada.
Ashkan AzimiInstitute of Medical Sciences, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
Rouwayda El-AyoubiNew World Laboratories, Laval, Quebec, H7V 5B7, Canada.
Alexander VelumianDivision of Neurosurgery, Department of Surgery, University of Toronto, Ontario, M5T 1P5, Canada.
Ilan VonderwaldeInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, M5S 3G9, Canada.
Cecile BoscherNew World Laboratories, Laval, Quebec, H7V 5B7, Canada.
Oana MihaiNew World Laboratories, Laval, Quebec, H7V 5B7, Canada.
Sarathi ManiNew World Laboratories, Laval, Quebec, H7V 5B7, Canada.
Marina SamoilovaDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, Ontario, M5T 2S8, Canada.
Mohamad KhazaeiDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, Ontario, M5T 2S8, Canada.
Michael G FehlingsInstitute of Medical Sciences, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
Cindi M MorsheadInstitute of Medical Sciences, University of Toronto, Toronto, Ontario, M5S 1A8, Canada. cindi.morshead@utoronto.ca.

Funding

CIHR
6 · The paper itself

Abstract

backgroundCell reprogramming is a promising avenue for cell-based therapies as it allows for the generation of multipotent, unipotent, or mature somatic cells without going through a pluripotent state. While the use of autologous cells is considered ideal, key challenges for their clinical translation include the ability to reproducibly generate sufficient quantities of cells within a therapeutically relevant time window.

methodsWe performed transfection of three distinct human somatic starting populations of cells with a non-integrating synthetic plasmid expressing Musashi 1 (MSI1), Neurogenin 2 (NGN2), and Methyl-CpG-Binding Domain 2 (MBD2). The resulting directly reprogrammed neural precursor cells (drNPCs) were examined in vitro using RT-qPCR, karyotype analysis, immunohistochemistry, and FACS at early and late time post-transfection. Electrophysiology (patch clamp) was performed on drNPC-derived neurons to determine their capacity to generate action potentials. In vivo characterization was performed following transplantation of drNPCs into two animal models (Shiverer and SCID/Beige mice), and the numbers, location, and differentiation profile of the transplanted cells were examined using immunohistochemistry.

resultsHuman somatic cells can be directly reprogrammed within two weeks to neural precursor cells (drNPCs) by transient exposure to Msi1, Ngn2, and MBD2 using non-viral constructs. The drNPCs generate all three neural cell types (astrocytes, oligodendrocytes, and neurons) and can be passaged in vitro to generate large numbers of cells within four weeks. drNPCs can respond to in vivo differentiation and migration cues as demonstrated by their migration to the olfactory bulb and contribution to neurogenesis in vivo. Differentiation profiles of transplanted cells onto the corpus callosum of myelin-deficient mice reveal the production of oligodendrocytes and astrocytes.

conclusionsHuman drNPCs can be efficiently and rapidly produced from donor somatic cells and possess all the important characteristics of native neural multipotent cells including differentiation into neurons, astrocytes, and oligodendrocytes, and in vivo neurogenesis and myelination.

Indexed as

Basic Helix-Loop-Helix ProteinsCell DifferentiationCells, CulturedCellular ReprogrammingDNA-Binding ProteinsElectrophysiologyFlow CytometryHumansKaryotypeMaleNerve Tissue ProteinsNeural Stem CellsNeurogenesisNeuronsRemyelinationRNA-Binding ProteinsBasic Helix-Loop-Helix ProteinsDNA-Binding ProteinsMBD2 protein, humanMSI1 protein, humanNerve Tissue ProteinsNEUROG2 protein, humanRNA-Binding ProteinsDirect reprogrammingdrNPCIn vivo neurogenesisIn vivo remyelinationNeural precursor cellsNeural stem cells

Identifiers

PMID31196173
PMCPMC6567617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.